Estrogen receptor α, but not β, plays a major role in 17β-estradiol-induced murine cholesterol gallstones

Gastroenterology

Volumn 127, Issue 1, 2004, Pages 239-249

  Wang, Helen H ^a   Afdhal, Nezam H ^a   Wang, David Q H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

17 estradiol; ABC; adenosine triphosphate binding cassette (transporter); cholesterol saturation index; CSI; diarylpropionitrile; DPN; ER; ER subtype ; ER subtype ; ER ; ER ; estrogen receptor; orchidectomized; ORX; OVX

Indexed keywords

4,4',4'' (4 PROPYL [1H] PYRAZOLE 1,3,5 TRIYL)TRISPHENOL; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHENOL DERIVATIVE; PROPIONITRILE; RECEPTOR SUBTYPE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL STONE; CONTROLLED STUDY; DIET; FEMALE; GALLSTONE FORMATION; GONADECTOMY; HYPOTHESIS; IMPLANTATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; STONE FORMATION;

EID: 3242694494     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.03.059     Document Type: Article

References (50)

1. Paigen B., Carey M.C. Gallstones. King R.A., Rotter J.F., Motulsky A.G. The genetic basis of common diseases. (1st ed). :2002;298-335 Oxford University Press, New York
2. Diehl A.K. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am. 20:1991;1-19
3. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet. 1:1973;1399-1404
4. Bennion L.J., Ginsberg R.L., Gernick M.B., Bennett P.H. Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med. 294:1976;189-192
5. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med. 290:1974;15-19
6. Grodstein F., Colditz G.A., Stampfer M.J. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 83:1994;5-11
7. Uhler M.L., Marks J.W., Judd H.L. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause. 7:2000;162-167
8. Simon J.A., Hunninghake D.B., Agarwal S.K., Lin F., Cauley J.A., Ireland C.C., Pickar J.H. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 135:2001;493-501
9. Henriksson P., Einarsson K., Eriksson A., Kelter U., Angelin B. Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest. 84:1989;811-816
10. Angelin B., Olivecrona H., Reihner E., Rudling M., Stahlberg D., Eriksson M., Ewerth S., Henriksson P., Einarsson K. Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterology. 103:1992;1657-1663
11. Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and action of estrogens. N Engl J Med. 346:2002;340-352
12. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology. 138:1997;863-870
13. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily the second decade. Cell. 83:1995;835-839
14. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G., Montano M., Sun J., Weis K., Katzenellenbogen J.A. Molecular mechanisms of estrogen action selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 74:2000;279-285
15. Iavarone M., Lampertico P., Seletti C., Francesca Donato M., Ronchi G., del Ninno E., Colombo M. The clinical and pathogenetic significance of estrogen receptor-β expression in chronic liver diseases and liver carcinoma. Cancer. 98:2003;529-534
16. Kraichely D.M., Sun J., Katzenellenbogen J.A., Katzenellenbogen B.S. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-α and estrogen receptor-β correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 141:2000;3534-3545
17. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazole ligands structure-affinity/activity relationships and estrogen receptor-α- selective agonists. J Med Chem. 43:2000;4934-4947
18. Harris H.A., Katzenellenbogen J.A., Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology. 143:2002;4172-4177
19. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-β potency-selective ligands structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem. 44:2001;4230-4251
20. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex) development of a novel, "pure" antiestrogen. Cancer. 89:2000;817-825
21. Hyder S.M., Chiappetta C., Murthy L., Stancel G.M. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 57:1997;2547-2549
22. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51:1991;3867-3873
23. Watanabe T., Inoue S., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A., Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype functional difference between estrogen receptors α and β Biochem Biophys Res Commun. 236:1997;140-145
24. Luo S., Martel C., Sourla A., Gauthier S., Merand Y., Belanger A., Labrie C., Labrie F. Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer. 73:1997;381-391
25. Wang D.Q.H., Paigen B., Carey M.C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice physical-chemistry of gallbladder bile. J Lipid Res. 38:1997;1395-1411
26. Wang D.Q.H. Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice. J Lipid Res. 43:2002;1950-1959
27. Wang D.Q.H., Lammert F., Paigen B., Carey M.C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice pathophysiology of biliary lipid secretion. J Lipid Res. 40:1997;2066-2079
28. Wang D.Q.H., Tazuma S., Cohen D.E., Carey M.C. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption studies in the gallstone-susceptible mouse. Am J Physiol. 285:2003;G494-G502
29. Wang D.Q.H., Carey M.C. Susceptibility to murine cholesterol gallstone formation is not affected by partial disruption of the HDL receptor SR-BI. Biochim Biophys Acta. 1583:2002;141-150
30. Rossi S.S., Converse J.L., Hofmann A.F. High pressure liquid chromatographic analysis of conjugated bile acids in human bile simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res. 28:1987;589-595
31. Bartlett G.R. Phosphorous assay in column chromatography. J Biol Chem. 234:1959;466-468
32. Carey M.C. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res. 19:1978;945-955
33. Akin M.L., Uluutku H., Erenoglu C., Karadag A., Gulluoglu B.M., Sakar B., Celenk T. Tamoxifen and gallstone formation in postmenopausal breast cancer patients retrospective cohort study. World J Surg. 27:2003;395-399
34. Couse J.F., Korach K.S. Estrogen receptor null mice what have we learned and where will they lead us? Endocr Rev. 20:1999;358-417
35. Ohashi A., Wang D.Q.H. 17β-Estradiol increases cholesterol cholelithogenesis in gallstone-resistant mice through mediating the expression of hepatic lipid transporters. (abstr) Gastroenterology. 122:2002;A7
36. Wang H.H., Afdhal N.H., Wang D.Q.H. The blockade of estrogen action by Fulvestrant (ICI 182,780) prevents cholesterol gallstone formation in the mouse. (abstr) Hepatology. 38:2003;195A
37. Everson G.T., McKinley C., Kern F. Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest. 87:1991;237-246
38. Kern F. Jr, Everson G.T. Contraceptive steroids increase cholesterol in bile mechanisms of action. J Lipid Res. 28:1987;828-839
39. Reichen J., Karlaganis G., Kern F. Jr. Cholesterol synthesis in the perfused liver of pregnant hamsters. J Lipid Res. 28:1987;1046-1052
40. Wang H.H., Afdhal N.H., Wang D.Q.H. Overexpression of estrogen receptor α inhibits the negative feedback regulation of hepatic cholesterol biosynthesis and increases newly synthesized cholesterol leading to biliary cholesterol hypersecretion. (abstr) Gastroenterology. 126:2004;A673
41. Ranelletti F.O., Piantelli M., Farinon A.M., Zanella E., Capelli A. Estrogen and progesterone receptors in the gallbladders from patients with gallstones. Hepatology. 14:1991;608-612
42. Singletary B.K., Van Thiel D.H., Eagon P.K. Estrogen and progesterone receptors in human gallbladder. Hepatology. 6:1986;574-578
43. Yamamoto M., Nakajo S., Tahara E. Immunohistochemical analysis of estrogen receptors in human gallbladder. Acta Pathol Jpn. 40:1990;14-21
44. Kern F. Jr, Everson G.T., DeMark B., McKinley C., Showalter R., Erfling W., Braverman D.Z., Szczepanik-van Leeuwen P., Klein P.D. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest. 68:1981;1229-1242
45. Kern F. Jr, Everson G.T., DeMark B., McKinley C., Showalter R., Braverman D.Z., Szczepanik-van Leeuwen P., Klein P.D. Biliary lipids, bile acids, and gallbladder function in the human female effects of contraceptive steroids. J Lab Clin Med. 99:1982;798-805
46. Keane P., Colwell D., Baer H.P., Clanachan A.S., Scott G.W. Effects of age, gender and female sex hormones upon contractility of the human gallbladder in vitro. Surg Gynecol Obstet. 163:1986;555-560
47. Radberg G., Friman S., Svanvik J. The influence of pregnancy and contraceptive steroids on the biliary tract and its reference to cholesterol gallstone formation. Scand J Gastroenterol. 25:1989;97-102
48. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Pro Natl Acad Sci U S A. 96:1999;1858-1862
49. Alarid E.T., Bakopoulos N., Solodin N. Proteasome-mediated proteolysis of estrogen receptor a novel component in autologous down-regulation. Mol Endocrinol. 13:1999;1522-1534
50. Preisler-Mashek M.T., Solodin N., Stark B.L., Tyriver M.K., Alarid E.T. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α Am J Physiol. 282:2002;E891-E898